Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel T-cell therapies for patients with cancer and autoimmune diseases. The company's lead product candidate, ADP-A2M, is a T-cell therapy that is currently in Phase 2 clinical trials for the treatment of multiple myeloma. Adaptimmune is also developing a pipeline of other T-cell therapies for the treatment of a variety of other cancers and autoimmune diseases.